Information  X 
Enter a valid email address

Edison Investment Research Lim (SDP)

  Print          Annual reports

Monday 29 November, 2021

Edison Investment Research Lim

IRLAB Therapeutics (IRLABA): Platform validated, pipeline momentum building

Edison Investment Research Limited
Edison Investment Research Limited: IRLAB Therapeutics (IRLABA): Platform validated, pipeline momentum building

29-Nov-2021 / 08:00 GMT/BST


 

London, UK, 29 November 2021

 

IRLAB Therapeutics (IRLABA): Platform validated, pipeline momentum building

The Ipsen deal for mesdopetam (IRL790) during Q321 was a significant achievement for IRLAB Therapeutics. It has provided strong external validation for IRLAB's ISP discovery platform and the $28m upfront payment has bolstered its cash runway. Moreover, with Ipsen now responsible for mesdopetam's Phase III development, additional resource has been freed up for IRLAB to kick on with its other programmes and further enrich its pipeline. Next up on the agenda is pirepemat (IRL752), which is due to start a Phase IIb trial for treatment of postural dysfunction and falls in Parkinson's disease (PD) by end-2021. IRLAB continues to make progress across its preclinical pipeline, with IRL942 potentially entering clinical development during 2022 for cognitive disorders. We value IRLAB at SEK5.2bn or SEK101/share.

 

Our valuation is virtually unchanged at SEK5.2bn or SEK101/share (SEK5.1bn or SEK99/share previously). We have updated for reported net cash, FX and rolled forward our model in time. Mesdopetam remains the largest value contributor at c SEK62/share for its potential use in PD-LIDs and PD-Psychosis; pirepemat's potential use in PD-Falls contributes c SEK31/share.


Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Dr Sean Conroy +44 (0)20 3077 5700 [email protected]

Dr Jonas Pecilius +44 (0)20 3077 5700 [email protected]

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn  www.linkedin.com/company/edison-group-/

Twitter   www.twitter.com/Edison_Inv_Res

YouTube  www.youtube.com/edisonitv



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1252243 29-Nov-2021 

fncls.ssp?fn=show_t_gif&application_id=1252243&application_name=news&site_id=financialexpress

a d v e r t i s e m e n t